High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids

Advanced Drug Delivery Reviews

Volumn 56, Issue 3, 2004, Pages 275-300

  Morissette, Sherry L ^a   Almarsson, Örn ^a   Peterson, Matthew L ^a   Remenar, Julius F ^a   Read, Michael J ^a   Lemmo, Anthony V ^a   Ellis, Steve ^a   Cima, Michael J ^b   Gardner, Colin R ^a  

^a TransForm Pharmaceuticals Inc   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Co crystal; Crystallization; High throughput; Polymorph; Salt; Solvate

Indexed keywords

COMPOSITION; CRYSTALLIZATION; CRYSTALS; SCREENING;

HIH-THROUGHPUT (HT) SCREENING; PATENT PROTECTION;

DRUG PRODUCTS;

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CIMETIDINE; FLURBIPROFEN; IBUPROFEN DERIVATIVE; INORGANIC SALT; ITRACONAZOLE; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; NICOTINAMIDE; PAROXETINE; PHENOBARBITAL; RANITIDINE; RITONAVIR; SACCHARIN; SERTRALINE; SOLVENT; SULFATHIAZOLE;

ANALYTIC METHOD; CHEMICAL BOND; CHEMICAL COMPOSITION; COMBINATORIAL CHEMISTRY; COMPUTER ANALYSIS; CRYSTAL; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CONTROL; DRUG DESIGN; DRUG FORMULATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EVAPORATION; EXPERIMENT; PATENT; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SOLID; SOLID STATE; TABLET; TECHNOLOGY; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

EID: 1042298890     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.020     Document Type: Article

References (113)

1. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs. 1999;SSCI, West Lafayette, IN.
2. Brittain H. Polymorphism in Pharmaceutical Solids. vol. 95:1999;Marcel Dekker, New York.
3. Berge S.M., Bighley L.D., Monkhouse D.C. Pharmaceutical salts. J. Pharm. Sci. 66:1977;1-19.
4. Gould P.L. Salt selection for basic drugs. Int. J. Pharm. 33:1986;201-217.
5. Threlfall T. Crystallisation of polymorphs: thermodynamic insight into the role of solvent. Org. Process Res. Dev. 4:2000;384-390.
6. Bernstein J. Crystal growth, polymorphism and structure-property relationships in organic crystals. J. Phys., D. Appl. Phys. 26:1993;B66-B76.
7. Bernstein J. Polymorphism in Molecular Crystals. 2002;Clarendon Press, Oxford.
8. Davey R., Garside J. From Molecules to Crystallizers. 2000;Oxford University Press, New York.
9. Guillory J. Generation of polymorphs, hydrates, solvates and amorphous solids. Brittain H. Polymorphism in Pharmaceutical Solids. vol. 95:1999;183-226 Marcel Dekker, New York.
10. Lahav M., Leiserowitz L. The effect of solvent on crystal growth and morphology. Chem. Eng. Sci. 56:2001;2245-2253.
11. Khoshkhoo S., Anwar J. Crystallization of polymorphs: the effect of solvent. J. Phys., D. Appl. Phys. 26:1993;B90-B93.
12. Blagden N., Davey R.J., Lieberman H.F., Williams L., Payne R.S., Roberts R.J., Rowe R.C., Docherty R. Crystal chemistry and solvent effects in polymorphic systems: sulfathiazole. J. Chem. Soc., Faraday Trans. 94:1998;1035-1044.
13. Davey R.J., Allen K., Blagden N., Cross W.I., Lieberman H.F., Quayle M.J., Righini S., Seton L., Tiddy G.J.T. Crystal engineering-nucleation, the key step. Cryst. Eng. Comm. 4:2002;257-264.
14. Caira M. Crystalline polymorphism of organic compounds. Top. Curr. Chem. 198:1998;163-208.
15. Ostwald W. Studien uber die Bildung und Umwandlung fester Korper. Z. Phys. Chem. 22:1897;289.
16. Leiserowitz L. To monitor and control nucleation of molecular crystals. Abstr.-Am. Chem. Soc. 223:2002;. 1.
17. Dunitz J.D. Are crystal structures predictable? Chem. Commun. 2003;545-548.
18. Vippagunta S.R., Brittain H.G., Grant D.J.W. Crystalline solids. Adv. Drug Deliv. Rev. 48:2001;3-26.
19. Weissbuch I., Shimon L.J.W., Landau E.M., Popovitzbiro R., Berkovitchyellin Z., Addadi L., Lahav M., Leiserowitz L. Tailormade auxiliaries for nucleation, growth and dissolution of organic-crystals. Pure Appl. Chem. 58:1986;947-954.
20. Weissbuch I., Addadi L., Lahav M., Leiserowitz L. Molecular recognition at crystal interfaces. Science. 253:1991;637-645.
21. Weissbuch I., Lahav M., Leiserowitz L. Toward stereochemical control, monitoring, and understanding of crystal nucleation. Cryst. Growth Des. 3:2003;125-150.
22. Blagden N., Cross W.I., Davey R., Broderick M., Pritchard R.G., Roberts R.J., Rowe R.C. Can crystal structure prediction be used as part of an integrated strategy for ensuring maximum diversity of isolated crystal form? The case of 2-amino-4nitrophenol. Phys. Chem. Chem. Phys. 3:2001;3819-3825.
23. Cross W., Blagden N., Davey R.J. A whole output strategy for polymorph screening: combining crystal structure prediction, graph set analysis and targeted crystallization experiments in the case of diflunisal. Cryst. Growth Des. 3:2003;151-158.
24. Davey R.J., Blagden N., Righini S., Alison H., Quayle M.J., Fuller S. Crystal polymorphism as a probe for molecular self-assembly during nucleation from solutions: the case of 2,6-dihydroxybenzoic acid. Cryst. Growth Des. 1:2001;59-65.
25. Mitchell C.A., Yu L., Ward M.D. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J. Am. Chem. Soc. 123:2001;10830-10839.
26. Rodriguez-Hornedo N., Lechuga-Ballesteros D., Wu H. Phase transition and heterogeneous epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int. J. Pharm. 85:1992;149-162.
27. Rodriguez-Hornedo N., Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 88:1999;651-660.
28. Lang M., Gzesiak A.L., Matzger A.J. The use of polymer heteronuclei for crystalline polymorph selection. J. Am. Chem. Soc. 124:2002;14834-14835.
29. Mohan R., Koo K., Strege C., Myerson A. Effect of additives on the transformation behavior of L-phenylalanine in aqueous solution. Ind. Eng. Chem. Res. 40:2001;6111-6117.
30. Masui Y., Kitaura Y., Kobayashi T., Goto Y., Ando S., Okuyama A., Takahashi H. Control of crystal habit and size of cefmatilen hydrochloride hydrate with a habit modifier. Org. Process. Res. Dev. 7:2003;334-338.
31. Beckmann W., Otto W., Budde U. Crystallisation of the stable polymorph of hydroxytriendione: seeding process and effects of purity. Org. Process. Res. Dev. 5:2001;387-392.
32. Blagden N., Davey R.J., Roberts R.J., Rowe R.C. Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole. Int. J. Pharm. 172:1998;169-177.
33. He X., Stowell J., Morris K., Pfeiffer R., Li H., Stahly P., Byrn S. Stabilization of a metastable polymorph of 4-methyl-2-nitroacetamide by isomorphic additives. Cryst. Growth Des. 1:2001;305-312.
34. Davey R.J., Blagden N., Potts G.D., Docherty R. Polymorphism in molecular crystals: stabilization of a metastable form by conformational mimicry. J. Am. Chem. Soc. 119:1997;1767-1772.
35. 2. Cryst. Growth Des. 2003;1-8.
36. 2. Pharm. Res. 18:2001;682-688.
37. Garetz B.A., Aber J.E., Goddard N.L., Young R.G., Myerson A.S. Nonphotochemical, polarization-dependent, laser-induced nucleation in supersaturated aqueous urea solutions. Phys. Rev. Lett. 77:1996;3475-3476.
38. Garetz B.A., Matic J., Myerson A.S. Polarization switching of crystal structure in the nonphotochemical light-induced nucleation of supersaturated aqueous glycine solutions. Phys. Rev. Let. 89:2002;175501.
39. Zaccaro J., Matic J., Myerson A.S., Garetz B.A. Nonphotochemical, laser-induced nucleation of supersaturated aqueous glycine produces unexpected gamma-polymorph. Cryst. Growth Des. 1:2001;5-8.
40. Peterson M.L., Morissette S.L., McNulty C., Goldsweig A., Shaw P., LeQuesne M., Monagle J., Encina N., Marchionna J., Johnson A., Gonzales-Zugasti J., Lemmo A.V., Ellis S.J., Cima M.J., Almarsson Ö. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. 124:2002;10958-10959.
41. Chyall L., Tower J., Coates D.A., Houston T.L., Childs S.L. Polymorph generation in capillary spaces: the preparation and structural analysis of a metastable polymorph of nabumetone. Cryst. Growth Des. 2:2002;505-510.
42. Hilden J.L., Reyes C.E., Kelm M.J., Tan J.S., Stowell J.G., Morris K.R. Capillary precipitation of a highly polymorphic organic compound. Cryst. Growth Des. 3(6):2003;921-926.
43. Walsh R.D.B., Bradner M.W., Fleishman S., Morales L.A., Moulton B., RodrÍgues-Hornedo N., Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases. Chem. Commun. 2003;186-187.
44. Remenar J.F., Morissette S.L., Peterson M.L., Moulton B., MacPhee M., Guzmán H., Almarsson Ö. Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J. Am. Chem. Soc. 215:2003;8456-8457.
45. Fleischman S.G., Kuduva S.S., McMahon J.A., Moulton B., Walsh R.D.B., Rodríguez-Hornedo N., Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst. Growth Des. 3(6):2003;909-919.
46. Storey R.A., Docherty R., Higginson P.D. Integration of high-throughput screening methodologies and manual processes for solid form selection. Am. Pharm. Rev. 2003 (Spring);100-105.
47. Desrosiers P. High-throughput screening techniques for pre-formulation: salt selection and polymorph studies, scientific update. International Symposium on Polymorphism and Crystallization:2001.
48. Blomsma E. Accelerating R&D by rational screening: solid form selection, scientific update. International Symposium on Polymorphism and Crystallization:2003.
49. van Langevelde A., Blomsma E. Preformulation: high-throughput screening in solid form selection. Acta Cryst., A. 58:2002;C9. (Supplement).
50. E.D. Carlson, P. Cong, W.H. Chandler, P.J. Desrosiers, J.C. Freitag, and J.F. Varni, Apparatuses and methods for creating and testing pre-formulations and systems for same, US Patent Appl. #20030116497.
51. Desrosiers P., Carlson E., Chandler W., Chau H., Cong P., Doolen R., Freitag C., Lin S., Masui C., Wu E., Crevier T., Mullins D., Song L., Lou R., Zhan J., Tangkilisan A., Ung Q., Phan K. High-throughput screening techniques for preformulation: salt selection and polymorph studies. Acta Cryst., A. 58:2002;C9. (Supplement).
52. Oldenburg K.R., Zhang J., Chen T., Maffia A., Blom K.F., Combs A.P., Chung T.D.Y. Assay miniaturization for ultra-high throughput screening of combinatorial and discrete compound libraries: a 9600-well (0.2 microliter) assay system. J. Biomol. Screen. 3:1998;55-62.
53. Almarsson Ö. High-throughput crystallization technology for polymorphism studies of pharmaceuticals, Scientific Update. International Symposium on Polymorphism and Crystallization:2003;. Chester, UK.
54. Cornell J.A. Experiments With Mixtures: Designs, Models, and the Analysis of Mixture Data. 1990;Wiley, New York.
55. Montgomery D.C. Response Surface Methods and Other Approaches to Optimization, Design and Analysis of Experiments. 2001;Wiley, New York.
56. Abola E., Kuhn P., Earnest T., Stevens R. Automation of X-ray crystallography. Nat. Struct. Bio., Structural Genomics Supplement. 2000;973-977.
57. Stewart L., Clark R., Behnke C. High-throughput crystallization and structure determination in drug discovery. DDT. 7:2002;187-196.
58. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., Poochikian G. Pharmaceutical solids - a strategic approach to regulatory considerations. Pharm. Res. 12:1995;945-954.
59. Morissette S.L., Read M., Soukasene S., Tauber M., Scoppettuolo L., Apgar J., Guzman H., Sauer J., Collins D., Jadhav P.K., Engler T., Gardner C.R. High-throughput crystallization of polymorphs and salts: applications in early lead optimization. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27:2003;. MEDI-301.
60. Morissette S.L., Soukasene S., Levinson D., Cima M.J., Almarsson O. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. PNAS. 100:2003;2180-2184.
61. Almarsson Ö, Hickey M.B., Peterson M.L., Morissette S.L., McNulty C., Soukasene S., Tawa M., MacPhee M., Remenar J.F. High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Cryst. Growth Des. 3(6):2003;927-933.
62. Stahl P.H., Nakano M. Pharmaceutical aspects of the drug salt form. Stahl P.H., Wermuth C.G. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. 2002;83-116 Wiley, New York.
63. Tong W., Whitesell G. In situ salt screening - a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol. 3:1998;215-223.
64. Morris K.R., Fakes M.G., Thakur A.B., Newman A.W., Singh A.K., Venit J.J., Spagnuolo C.J., Serajuddin A.T.M. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105:1994;209-217.
65. C.R. Gardner, O. Almarsson, H. Chen, S.L. Morissette, M.L. Peterson, Z. Zhang, S. Wang, A.V. Lemmo, J. Gonzales-Zugasti, J. Monagle, J. Marchionna, S.J. Ellis, C. McNulty, A. Johnson, D. Levinson, and M.J. Cima, Application of high-throughput technologies to drug substance and drug product development, Computers and Chemical Engineering (in press).
66. Bastin R.J., Bowker M.J., Slater B.J. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Process. Res. Dev. 4:2000;427-435.
67. McCrone W. Physics and Chemistry of the Organic Solid State. 1965;725-767 Wiley Interscience, New York.
68. Burroughs Wellcome v. Barr Laboratories, 40 F.3d 1223 (Fed. Cir. 1994).
69. Bayer v. Barr Laboratories, 39 USPQ2d 1862 (S.D.N.Y. 1996).
70. Eli Lilly and Co. v. Barr Laboratories, Civil Action No. 96-491 (S.D. Ind. 2003).
71. Imperial Chemical Industries v. Barr Laboratories, 795 F. Supp. 619 (S.D.N.Y. 1992).
72. Glaxo v. Geneva Pharmaceuticals, Civil Action No. 94-1921 (D.N.J.). 2003).
73. Marion Merrell Dow v. Geneva Pharmaceuticals, 877 F. Supp. 531 (D. Colo 1994).
74. Burroughs Wellcome v. Barr Laboratories, 40 F.3d 1223 (Fed. Cir. 1994).
75. Glaxo v. Novopharm, 52 F.3d 1043 (Fed. Cir. 1995).
76. Glaxo v. Novopharm, 42 USPQ2d 1257 (Fed. Cir. 1997).
77. Zeneca v. Novopharm, No. 96-1364, 1997 U.S. App. LEXIS 6634 (Fed. Cir. 4-10-1997).
78. Abbott Laboratories v. Novopharm, 41 USPQ2d 1535 (Fed. Cir. 1997).
79. Schering Corp. v. FDA, 51 F.3d 390, 392 n. 1 (3d Cir. 1995).
80. Payne R.S., Rowe R.C., Roberts R.J., Charlton M.H., Docherty R. Potential polymorphs of aspirin. J. Comput. Chem. 20:1999;262-273.
81. Schwartzman G. Does aspirin exist in polymorphic states? J. Pharm. Pharmacol. 24:1972;169-170.
82. Burger A. Zur Interpretation von Polymorphie-Untersuchungen. Acta Pharm. Technol. 28:1982;1-20.
83. Lang M., Kampf J.W., Matzger A.J. Form IV of carbamazepine. J. Pharm. Sci. 91:2002;1186-1190.
84. ICH Steering Committee, Good manufacturing practice guide for active pharmaceutical ingredients Q7a, ICH harmonised tripartite guidelines, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (11-10-2000); also published in the Federal Register, vol. 66, No. 186, September 25, 2001, 49028-49029.
85. Anquetil P.A., Brenan C.J.H., Marcolli C., Hunter I.W. Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes. J. Pharm. Sci. 92:2003;149-160.
86. Starbuck C., Spartalis A., Wai L., Wang J., Fernandez P., Lindemann C.M., Zhou G.X., Ge Z.H. Process optimization of a complex pharmaceutical polymorphic system via in situ Raman spectroscopy. Cryst. Growth Des. 2:2002;515-522.
87. Jahansouz H., Thompson K.C., Brenner G.S., Kaufman M.J. Investigation of the polymorphism of the angiotensin II antagonist MK-996. Pharm. Dev. Technol. 4:1999;181-187.
88. Dunitz J.D., Bernstein J. Disappearing polymorphs. Acc. Chem. Res. 28:1995;193-200.
89. Teva Pharmaceuticals Industries, Novel sertraline hydrochloride polymorphs, process for preparing them, compositions containing them and methods of using them, PCT/US00/35178.
90. Teva Pharmaceuticals Industries, Sertraline hydrochloride polymorphs, PCT WO 00/32551.
91. Pfizer, Sertraline polymorph, US Patent #5,248,699.
92. Torcan Chemical, Sertraline polymorph having improved water solubility, EP 0928784A1.
93. Byrn S.R., Pfeiffer R.R., Stephenson G., Grant D.J.W., Gleason W.B. Solid-state pharmaceutical chemistry. Chem. Mater. 6:1994;1148-1158.
94. Bugay D.E. Characterization of the solid-state: spectroscopic techniques. Adv. Drug Deliv. Rev. 48:2001;43-65.
95. Stephenson G.A., Forbes R.A., Reutzel-Edens S.M. Characterization of the solid state: quantitative issues. Adv. Drug Deliv. Rev. 48:2001;67-90.
96. Bernstein J. Polymorphism and patents. Polymorphism in Molecular Crystals. 2002;297-307 Oxford University Press, New York.
97. Sklar S.R. Paxil® and polymorph patents: have things gone from bad to worse for big pharma? Pharm. Law Ind. 1:2003;312-316.
98. Bauer J., Spanton S., Henry R., Quick J., Dziki W., Porter W., Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18:2001;859-866.
99. Chemburkar S.R., Bauer J., Deming K., Spiwek H., Patel K., Morris J., Henry R., Spanton S., Dziki W., Porter W., Quick J., Bauer P., Donaubauer J., Narayanan B.A., Soldani M., Riley D., McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process. Res. Dev. 4:2000;413-417.
100. S. Price, Computer prediction of pharmaceutical solid polymorphs, Adv. Drug Del. Rev. (ibid).
101. Cambridge Structural Database ConQuest Version 1.5. 2003;Cambridge Crystallographic Data Center (CDCC), Cambridge, United Kingdom.
102. Leusen F.J.J. Crystal structure prediction of diastereomeric salts: a step toward rationalization of racemate resolution. Cryst. Growth Des. 3:2003;189-192.
103. Gavezzotti A. Ten years of experience in polymorph prediction: what next? Cryst. Eng. Com. 4:2002;343-347.
104. Lommerse J.P.M., Motherwell W.D.S., Ammon H.L., Dunitz J.D., Gavezzotti A., Hofmann D.W.M., Leusen F.J.J., Mooij W.T.M., Price S.L., Schweizer B., Schmidt M.U., van Eijck B.P., Verwer P., Williams D.E. A test of crystal structure prediction of small organic molecules. Acta Cryst., B. 56:2000;697-714.
105. Verwer P., Leusen F.J.J. Computer simulations to predict possible crystal polymorphs. Rev. Comput. Chem. 1998;327-365 Wiley, New York.
106. Motherwell W.D.S., Ammon H.L., Dunitz J.D., Dzyabchenko A., Erk P., Gavezzotti A., Hofmann D.W.M., Leusen F.J.J., Lommerse J.P.M., Mooij W.T.M., Price S.L., Scheraga H., Schweizer B., Schmidt M.U., van Eijck B.P., Verwer P., Williams D.E. Crystal structure prediction of small organic molecules: a second blind test. Acta Cryst., B. 58:2002;647-661.
107. Beyer T., Day G.M., Price S.L. The prediction, morphology, and mechanical properties of the polymorphs of paracetamol. J. Am. Chem. Soc. 123:2002;5086-5094.
108. Oswald I.D.H., Allan D.R., McGregor P.A., Motherwell W.D.S., Parsons S., Pulham C.R. The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors. Acta Crystallographica. B58:2002.
109. Somerville K.B., Sider D.R., Sager J.W., Vydra V.K., Mathre D.J. Application of Lab Automation to High-throughput Solubility Studies. 2001;Laboratory Robotics Interest Group, Boston, MA.
110. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2002;235-249.
111. Yu L., Stephenson G.A., Mitchell C.A., Bunnel C.A., Snorek S.V., Bowyer J.J., Borchardt T.B., Stowell J.G., Byrn S.R. Thermochemistry and conformational polymorphism of a hexamorphic system. J. Am. Chem. Soc. 122:2000;585-591.
112. Yu L. Color changes caused by conformational polymorphism: optical-crystallography, single-crystal spectroscopy, and computational chemistry. J. Phys. Chem., A. 106:2002;544-550.
113. Apperley D.C., Fletton R.A., Harris R.K., Lancaster R.W., Tavener S., Threlfall T.L. Sulfathiazole polymorphism studied by magic-angle spinning NMR. J. Pharm. Sci. 88:1999;1275-1280.